The earnings call reveals mixed signals. Positives include potential $37 million milestone payment from OpRegen, new manufacturing processes, and strategic partnerships. However, the significant net loss, unclear management responses, and reliance on future funding present risks. The Q&A highlights potential expansion with the CIRM grant and partnership strategies, but uncertainties remain. Overall, the sentiment is balanced, leading to a neutral stock price prediction.